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Abstract
Background: Current guidelines recommend that patients with Staphylococcus aureus bloodstream infection (SAB)
are treated with long courses of intravenous antimicrobial therapy. This serves to avoid SAB-related complications
such as relapses, local extension and distant metastatic foci. However, in certain clinical scenarios, the incidence of
SAB-related complications is low. Patients with a low-risk for complications may thus benefit from an early switch to
oral medication through earlier discharge and fewer complications of intravenous therapy.
The major objective for the SABATO trial is to demonstrate that in patients with low-risk SAB a switch from intravenous
to oral antimicrobial therapy (oral switch therapy, OST) is non-inferior to a conventional course of intravenous therapy
(intravenous standard therapy, IST).
Methods/Design: The trial is designed as randomized, parallel-group, observer-blinded, clinical non-inferiority
trial. The primary endpoint is the occurrence of a SAB-related complication (relapsing SAB, deep-seated infection, and
attributable mortality) within 90 days. Secondary endpoints are the length of hospital stay; 14-day, 30-day, and 90-day
mortality; and complications of intravenous therapy. Patients with SAB who have received 5 to 7 full days of adequate
intravenous antimicrobial therapy are eligible. Main exclusion criteria are polymicrobial bloodstream infection, signs
and symptoms of complicated SAB (deep-seated infection, hematogenous dissemination, septic shock, and prolonged
bacteremia), the presence of a non-removable foreign body, and severe comorbidity. Patients will receive either OST or
IST with a protocol-approved antimicrobial and are followed up for 90 days. Four hundred thirty patients will be
randomized 1:1 in two study arms. Efficacy regarding incidence of SAB-related complications is tested sequentially with
a non-inferiority margin of 10 and 5 percentage points.
Discussion: The SABATO trial assesses whether early oral switch therapy is safe and effective for patients with low-risk
SAB. Regardless of the result, this pragmatic trial will strongly influence the standard of care in SAB.
Trial registration: ClinicalTrials.gov NCT01792804 registered 13 February 2013; German Clinical trials register
DRKS00004741 registered 4 October 2013, EudraCT 2013-000577-77. First patient randomized on 20 December 2013.
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Background
Increasing resistance to antimicrobial agents is recog-
nized as a major health problem worldwide and is com-
pounded by the dearth of new antimicrobial agents
currently in development [1]. This threat underscores
the need to maximize the clinical utility of existing anti-
microbials through more rational prescription, for ex-
ample, by optimizing the duration of treatment. The
SABATO trial will assess whether the duration of intra-
venous therapy can be reduced in Staphylococcus aureus
bloodstream infection (SAB).
SAB is a major cause of prolonged antimicrobial ther-
apy. With an approximate incidence of 25 cases per
100,000 population per year, there are about 200,000
cases annually in Europe [2]. Recent data for Western
Europe demonstrate a crude mortality of 20-30 % (in-
hospital or 30-day mortality) in patients with SAB [2].
In many cases SAB can be cured by antimicrobial
therapy. However, SAB differs from other bloodstream
infections with respect to SAB-related complications.
Relapse, local extension and distant metastatic foci are
relatively common events and occur in about 2 to 25 %
of infections [3–5]. It is believed that these complica-
tions can be minimized by an adequate length of
antimicrobial therapy. Therefore, standard treatment
schedules are much longer than for other bloodstream
infections. For example, a course of at least 14 days of
intravenous antimicrobials is considered standard ther-
apy in “uncomplicated SAB” [6–8], whereas even longer
courses are required in “complicated” disease. Shorter
courses of intravenous treatment are currently not rec-
ommended due to the lack of sound clinical evidence.
However, these recommendations are based on expert
opinion and a few observational studies.
The hypothesis of the SABATO trial is that a switch
from intravenous to oral antimicrobial therapy is non-
inferior to standard intravenous therapy in patients with
low-risk SAB. Therefore, the primary objective of the
trial is to demonstrate that oral switch therapy (OST) is
as safe and effective as intravenous standard therapy
(IST). This will be achieved by comparing the rate of
SAB-related complications (relapsing SAB, deep-seated
infection with S. aureus, or mortality attributable to
SAB) within 90 days.
Abbreviated treatment courses or early intravenous to
oral switch treatment strategies have been successfully
applied to other infectious diseases such as nosocomial
pneumonia [9], meningococcal disease [10], and febrile
neutropenia [11]. These strategies allow shorter intra-
venous antimicrobial therapy and offer options for early
discharge from hospital. This, in turn, increases the pa-
tients’ quality of life, decreases treatment costs, reduces
the risk of nosocomial infections and may help to dimin-
ish antimicrobial resistance development and spread.
Regarding SAB, there is one controlled randomized
study where 16 of 36 patients received short-course
therapy consisting of 2 weeks intravenous nafcillin
[12]. A difference in complication rate between pa-
tients who received 2 or 4 weeks of intravenous anti-
microbial treatment could not be detected. However,
a meta-analysis of this controlled trial and 10 uncon-
trolled, epidemiological studies [13] showed potential
bias and considerable imprecision and recommended
further trials. The effectiveness of oral antimicrobial
therapy in SAB has been assessed in a single random-
ized controlled trial [14]: 104 patients with SAB either
received oral fleroxacin plus rifampicin or intravenous
study therapy. The cure rate in both groups was simi-
lar (82 % versus 80 %), and patients on oral medica-
tion were discharged earlier, although they had more
drug-related adverse events. This study suggests that
orally administered antimicrobials may be as effective
as intravenous therapy.
Although not supported by current recommendations,
shorter duration of intravenous therapy has become
management practice for SAB in some countries:
Thwaites et al. reviewed management practices of pa-
tients with SAB in eight UK centers and found that 25 %
of patients received oral antimicrobials alone for more
than 50 % of the treatment duration whereas 16 % of pa-
tients received less than the recommended 14 days of
therapy [15]. In this study, the efficacy and safety of oral
therapy were not assessed.
In this trial, a population of patients with a very low
risk of SAB-related complications is selected by rigorous
inclusion and exclusion criteria. The selection criteria
are based on data from two prospective cohort studies.
Data from the INSTINCT (Invasive Staphylococcus
aureus Infection Cohort) study [16, 17] show a low inci-
dence of SAB-related complications in low-risk patients
(3 %; four of 135 patients). A pilot study for the
SABATO trial with 236 SAB patients from 10 German
study centers [18] provided further evidence for a very
low risk of complications, with a single SAB-related
complication occurring in 89 patients.
In addition, an early switch to oral medication may
also improve patients’ well-being: an abbreviated hos-
pital stay can increase quality of life and reduces the risk
of intravascular line-associated inflammation or infec-
tion. There may also be benefits for healthcare institu-
tions, such as cost-savings afforded by reduced length of
stay or reduced use of outpatient parenteral antimicro-
bial therapy (OPAT) services.
A successfully performed trial will have a great impact
on clinical decision making worldwide. Regardless of its
outcome, it will provide a rationale for optimizing treat-
ment of patients with low-risk SAB - a common clinical
scenario - that will be integrated into evidence-based
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treatment guidelines. We will therefore perform a multi-
center, center stratified, observer-blinded, randomized,
parallel-group, clinical non-inferiority trial with the aim
to provide a definitive answer.
Methods/Design
Study hypothesis and aims
The aim of the trial is to demonstrate that in patients
with low-risk SAB a switch from intravenous to oral
antimicrobial therapy is non-inferior to a conventional
14-day course of intravenous therapy. This will be
achieved by comparing the rate of SAB-related compli-
cations (relapsing SAB, deep-seated infection with S.
aureus, or mortality attributable to SAB) within 90 days
between OST and IST. The secondary objective is to es-
timate the potential benefit for the patient by evaluating
the length of hospital stay after the first positive blood
culture, all-cause mortality, and complications of intra-
venous therapy.
Setting
The study will be performed in the following 19 uni-
versity or teaching hospitals in four European coun-
tries including the following: in Germany - Uniklinik
Köln, University Hospital Freiburg, Vivantes Auguste-
Viktoria-Klinikum Berlin, Hannover Medical School, Jena
University Hospital, Universitätsklinikum Aachen, Helios
Klinikum Krefeld, University of Schleswig-Holstein
Lübeck, Klinikum Leverkusen, University Hospital
Regensburg, and J.W. Goethe University Hospital Frankfurt;
in The Netherlands - University Medical Center Groningen,
Amphia Hospital Breda, Sint Elisabeth Hospital Tilburg,
Academic Medical Center Amsterdam, and University
Medical Center Utrecht; in Spain - Hospital Clínic of
Barcelona, Hospital Universitario Virgen Macarena Sevilla,
and Hospital Universitario Virgen del Rocío Sevilla; and in
the United Kingdom - Nottingham University Hospitals
NHS Trust.
Ethical and regulatory considerations
The trial will be conducted in accordance with the pub-
lished principles of the guidelines for Good Clinical
Practice (ICH-GCP) and applicable legislation (especially
the Federal Drug Law (AMG) and the GCP-V). The
study protocol was approved by the Ethics Committees
of all participating centers and the respective competent
authorities (a list is provided in an additional file [see
Additional file 1]). Informed consent is obtained from
each participant.
The final trial report will follow the CONSORT state-
ment and its extension to non-inferiority and equiva-
lence trials [19].
Patient selection and sex distribution
Patients with SAB from all disciplines are reported from
the microbiological department to the site investigator
as soon as S. aureus is identified in the blood culture
(Fig. 1). Then, individual patients with SAB are assessed
for possible enrollment. They will be considered for
enrollment when all inclusion criteria and none of the
exclusion criteria are fulfilled. All eligible patients are
hospital inpatients.
SAB is more frequent in male patients (m:f = 2:1) [20].
The reason for this phenomenon is not known. Since
most infections arise from the skin and nasal flora of the
patient, this may reflect a higher nasal colonization rate
in men [21, 22]. However, mortality does not vary
between the male and female sex [20]. Sex-specific dif-
ferences in efficacy and safety of the study drugs are not
expected; however, this will be investigated.
Inclusion and exclusion criteria
Inclusion and exclusion criteria are designed to select a
group of patients with SAB that have a low risk for SAB-
related complications. Patients entering the study will
have already received 5 to 7 days of adequate intraven-
ous antimicrobial therapy and have no signs and symp-
toms of complicated S. aureus infection prior to
enrollment. Patients with a higher a priori risk for SAB-
related complications are excluded (for example, severe
immunosuppression, end-stage renal disease, and pres-
ence of non-removable foreign body). Details of inclu-
sion and exclusion criteria are presented in Table 1.
Patient randomization
Patients are randomly allocated to treatment arms (1:1)
no earlier than 1 day before starting the study drug. This
is achieved by a central 24/7 Internet randomization ser-
vice TENALEA (stratified by study center and with per-
muted blocks of varying length). Authorized local study
staff may login to a secure website, randomize a patient
and receive an email with an attached pdf document
giving all the details on the allocated treatment. The
randomization service is set up and maintained by
the Institute of Medical Statistics, Informatics and
Epidemiology (IMSIE), University of Cologne.
Treatment of patients
Treatment of patients in this observer-blinded study fol-
lows a pragmatic approach. All study medication is com-
mercially available and approved by the respective
national authorities. Study medication is used as mar-
keted in standard dosing regimens. According to the
treatment arm, patients will either receive an oral or
intravenous study drug. The study drug will be selected
by the site investigator from a list of drugs (Table 2), de-
pending on the susceptibility of the respective isolate,
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expected drug interactions, contraindications, and ex-
pected side effects. Investigators will first assess whether
the “first-choice” regimen can be given and then con-
sider the alternative regimen. The study drug can also be
switched during therapy from first choice to the respect-
ive alternative medication. Early discontinuation of study
drug or combination therapy (for example, addition of
gentamicin, rifampicin, or fosfomycin) is regarded as a
protocol violation. Dose adjustments in the individual
patients will be performed as judged appropriate by the
site investigator following the guidelines in Table 2.
Study drug will be discontinued after 7 to 9 days
(depending on the length of antimicrobial therapy before
randomization) so that patients receive an overall course
of 14 days of antimicrobial therapy.
Assessment and follow-up
All patients will be followed for 90 days to evaluate effi-
cacy and safety variables. To assess outcome measures,
patients will be visited on the ward by the clinical team
while in the hospital according to the visit schedule
(Table 3). Discharged patients are followed by a struc-
tured telephone interview. All data will be recorded on
electronic case report forms. Patients on OST can be
discharged before the end of therapy (EOT) according to
clinical and psychosocial criteria. Patients on IST can
only be discharged when an OPAT service is in oper-
ation at the local study site.
Outcome measures
The primary endpoint, SAB-related complication, de-
fined as relapsing SAB, deep-seated infection, or attrib-
utable mortality, will be derived from patient interviews,
laboratory reports, and clinical evaluation. Patients with
either condition will be classified as “failure.” SAB-
related complications are classified as either “microbio-
logically documented” or “clinically suspected.” To
qualify for a “microbiologically documented” relapsing
SAB or deep-seated infection, the S. aureus isolate needs
to exhibit the same characteristics as the original infect-
ing isolate (based on antimicrobial susceptibility and
genotyping tests as appropriate), and not to be considered
by the local investigator to represent a contaminant.
Relapsing SAB is defined as positive blood culture for
S. aureus within the intervention or follow-up period.
Proven catheter-related SAB during the follow-up period
is not considered relapsing SAB, since catheter-related
infection is highly likely the result of a new infection.
Catheter-related blood-stream infection is considered
“proven,” if (1) the same S. aureus strain is recovered
Fig. 1 Trial flowchart
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Table 1 Inclusion and exclusion criteria
Inclusion criteria Exclusion criteria
• Age at least 18 years • Polymicrobial bloodstream infection, defined as isolation of pathogens
other than S. aureus from a blood culture obtained in the time from
two days prior to the first positive blood culture with S. aureus until
randomization. Common skin contaminants (coagulase-negative
staphylococci, diphtheroids, Bacillus spp., and Propionibacterium spp.)
detected in one of several blood cultures will not be considered to
represent polymicrobial infection
• Not legally incapacitated
• Written informed consent from the trial subject has been obtained
• Blood culture positive for Staphylococcus aureus not considered to
represent contamination
• At least one negative follow-up blood culture obtained within 48 to
72 hours after the start of adequate antimicrobial therapy to rule out
persistent bacteremia
• Recent history (within 3 months) of prior S. aureus bloodstream infection
• Five to 7 full days of appropriate i.v. antimicrobial therapy administered
prior to randomization documented in the patient chart. Appropriate
therapy has all of the following characteristics:
• In vitro resistance of S. aureus to all oral or all i.v. study drugs
• Contraindications in reference document for all oral or all i.v. study drugs
- Antimicrobial therapy has to be initiated within 72 h after the first
positive blood culture was drawn.
• Previously planned treatment with active drug against S. aureus during
intervention phase (for example, cotrimoxazole prophylaxis)
- Provided in-vitro susceptibility and adequate dosing (as judged
by the principal investigator) preferred agents for pre-randomization
antimicrobial therapy are: flucloxacillin, cloxacillin, vancomycin, and
daptomycin. However, the following parenteral antimicrobials are
allowed: MSSA: penicillinase-resistant penicillins (for example,
flucloxacillin and cloxacillin), β-lactam plus β-lactamase-inhibitors
(for example, ampicillin + sulbactam, piperacillin + tazobactam),
cephalosporins (except ceftazidime), carbapenems, clindamycin,
fluoroquinolones, trimethoprim-sulfamethoxazole, doxycycline,
tigecycline, vancomycin, teicoplanin, linezolid, daptomycin,
ceftaroline, and macrolides. MRSA: vancomycin, teicoplanin,
fluoroquinolones, clindamycin, trimethoprim-sulfamethoxazole,
doxycycline, tigecycline, linezolid, daptomycin, macrolides, and
ceftaroline
• Signs and symptoms of complicated SAB as judged by an ID physician.
Complicated infection is defined as at least one of the following:
- deep-seated focus: for example, endocarditis, pneumonia, undrained
abscess, empyema, and osteomyelitis
- septic shock, as defined by the AACP criteria [32], within 4 days before
randomization
- prolonged bacteremia: positive follow-up blood culture more than 72 h
after the start of adequate antimicrobial therapy
- body temperature > 38 °C on 2 separate days within 48 h before
randomization
• Presence of a non-removable foreign body (if not removed two days
or more before randomization):
- prosthetic joint
- prosthetic heart valve
- vascular graft
- pacemaker
- automated implantable cardioverter-defibrillator
- ventriculo-atrial shunt
• Failure to remove any intravascular catheter, which is present when first
positive blood culture was drawn within 4 days of the first positive blood
culture
• Severe liver disease
• End-stage renal disease
• Severe immunodeficiency:
- primary immunodeficiency disorders
- neutropenia (<500 neutrophils/μl) at randomization or neutropenia
expected during intervention phase due to immunosuppressive treatment
- uncontrolled disease in HIV-positive patients
- high-dose steroid therapy (>1 mg/kg prednisone or equivalent doses
given for > 4 weeks or planned during intervention)
- immunosuppressive combination therapy with two or more drugs with
different mode of action
- hematopoietic stem cell transplantation within the past 6 months or
planned during treatment period
- solid organ transplant
- treatment with biological
• life expectancy < 3 months
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from a blood culture and from the catheter tip, or from
the blood culture and from pus or a skin swab obtained
from the catheter exit site, or if two initial sets of blood
cultures positive for S. aureus show a positive differential
time to positivity and there is no other plausible source
of SAB.
Deep-seated infection is any deep-seated focus of S.
aureus infection resulting from hematogenous dissemin-
ation (such as infective endocarditis according to the
modified Duke criteria [23], osteomyelitis, or suppura-
tive arthritis). Diagnosis requires either a culture positive
with S. aureus from the respective site or a blood culture
positive with S. aureus plus imaging studies showing the
presumed focus. Catheter-related infections, superficial
skin-and soft tissue or wound infections do not qualify
as “deep-seated,” since they are highly likely to result
from a new infection.
Death will be attributed to SAB when at least one of
the following conditions is present [16]: a positive blood
culture for S. aureus drawn within 72 h before death, or
a persistent focus of deep-seated S. aureus infection at
time of death, or persistent signs and symptoms of sys-
temic infection at time of death as judged by a study
physician, or a post-mortem analysis proving a S. aureus
related complication as cause of death.
The secondary endpoints are the length of hospital
stay (reflects the potential benefits for patients who
have been switched to oral medication), 14-day sur-
vival, 30-day survival, 90-day survival, and complica-
tions related to i.v. therapy, such as chemical or
septic thrombophlebitis. The safety of study drugs is
assessed by monitoring Clostridium difficile-associated
diarrhea, and all (severe) adverse events that meet
grade 3 or above of the Common Terminology Criteria of
Adverse Events (Version 4.0) [24].
Sample size
Since a non-inferiority margin of 10 percentage points
seems to be too high for the clinical question to be ad-
dressed, the study sample size was calculated to ensure
sufficient power (that is, 80 %) even with a reduced mar-
gin of 5 percentage points (as a compromise of precision
Table 1 Inclusion and exclusion criteria (Continued)
• Inability to take oral drugs
• Injection drug user
• Expected low compliance with drug regimen
• Participation in other interventional trials within the previous three
months or ongoing
• Pregnant women and nursing mothers
• For premenopausal women: Failure to use highly-effective contraceptive
methods for 1 month after receiving study drug.
• Persons with any kind of dependency on the investigator or employed
by the sponsor or investigator
• Persons held in an institution by legal or official order
Table 2 Choice of study drugs and suggested dosing
OST Minimum daily dose Suggested regimen Acceptable dosing Dose adjustment
First choice for MSSA and MRSA:
trimethoprim-sulfamethoxazole
320/1600 mg 160/800 mg twice a day Severe renal impairment
Alternative for MSSA: clindamycin 1800 mg 600 mg three times a day No
Alternative for MRSA: linezolid 1200 mg 600 mg twice a day No
IST
First choice for MSSA: flucloxacillin 6 g (in at least four doses a
day, or continuous infusion)
2 g four times a day 4 g three times a day Severe renal impairment
First choice MSSA in Spain: cloxacillin 6 g (in at least four doses a
day, or continuous infusion)
2 g four times a day 2 g six times a day No
Alternative for MSSA: cefazolin 1 g three times a day 2 g three times a day 3 g four times a day Renal impairment
Alternative for MSSA and first choice
for MRSA: vancomycin
as determined by therapeutic
drug monitoring
1 g twice a day 20 mg/kg three times a day;
loading dose and continuous
infusion are accepted
TDM (suggested level:
10 to 20 μg/ml)
Alternative for MRSA: daptomycin 6 mg/kg once per day 6-10 mg/kg once per day Renal impairment
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and feasibility). Both margins, that is, 10 % and 5 %, are
tested hierarchically to ensure both sufficient power and
type I error control [25].
A large prospective cohort study of 324 SAB patients
indicates that patients with a removable focus of infec-
tion have a low risk (2.4 %) for late complications [26].
In a similar prospective study of 211 SAB patients with a
removable focus of infection, the relapse rate with anti-
microbial therapy for less than 14 days (n = 134) was
3.7 % [27]. A meta-analysis of studies performed be-
tween 1967 and 1993 reported a combined rate of late
complications of 6.1 % in patients with catheter-related
infections [13]. When using inclusion and exclusion
criteria for low-risk patients, our own studies showed
complication rates of 1 % (preSABATO) and 3 %
(INSTINCT). Therefore, we estimate an incidence of
2.5 % of late complications in study patients.
Thus, the necessary sample size for each study arm is
165.8 (non-inferiority margin 5 %, one-sided α = 0.05,
β = 0.2, one interim analysis at information fraction
0.5 using the O’Brien-Fleming bound 2.373; calculated
using ADDPLAN 6.0.1, ADDPLAN GmbH, Cologne).
An allowance of 10 % for deaths unrelated to SAB, of
10 % for protocol violations and of 5 % for stratifi-
cation yields 331.6/0.9/0.9/0.95, approximately 430 pa-
tients in total need to be randomized. Of note, if
non-attributable mortality (that is, about 10 % within
90 days) were added to the composite endpoint, the
sample size needed would approximately double (that
is, from 430 to 823 patients). Unfortunately, this can-
not be achieved by the clinical network.
At the interim analysis, observations of 2.5 % late
complications, that is, 0.025*166/2 ≈ 2 in each group,
yields a 98.235 % confidence interval (corresponding to
the O’Brien-Fleming bound 2.373) for the difference
of -8.2 % to +8.2 % (Newcombe’s method; [28]). At
the final analysis (as planned) observations of 2.5 %
late complications, that is, 0.025*166 ≈ 4 in each group,
yields a 91.765 % confidence interval (corresponding to
the O’Brien-Fleming bound 1.678) for the difference
of -3.4 % to +3.4 %.
Statistical analysis
All analyses will be done on three study populations
(Fig. 2). The primary analysis set is derived from the
per-protocol (PP) population. This dataset includes all
study subjects who were essentially treated according to
protocol and reached a defined endpoint in the trial
(SAB-unrelated deaths will be excluded). The evaluabil-
ity of study subjects will be assessed in a blinded manner
by the Clinical Review Committee.
The secondary analysis set is derived from the
intention-to-treat (ITT) population. This dataset in-
cludes all randomized study subjects, analyzed as
assigned, with indeterminate and missing outcomes
counted as failures. Following current recommendations,
CPMP/EWP/558/95 rev 2 [29] and CPMP/EWP/482/99
[30], the primary analysis is based on the per-protocol
set; the analysis of the full analysis set (intention-to-
treat, all randomized patients) will be of equal import-
ance and should lead to similar conclusions for a robust
interpretation.
The tertiary analysis set is the safety population. This
dataset includes all study subjects who received any
study drug.
The possibly adaptive interim analysis based on 215
included patients (at information fraction 0.5) serves to
Table 3 Visit schedule
Screening Treatment EOS
Visit number 0 1 2 3
Day -5 to -1 1 7 to 11
(EOT)
85 to 99
Informed consent X
Check in/exclusion criteria X
Randomization X
Demographic data X
Medical history X
Charlson score X
Pitt bacteremia score X
Current medication X X X X
Infective focus X
Clinical data
Physical examination X X
Vital signs X X
Outcome assessment
SAB-related complications X X
Length of stay (in days) X X
90-day mortality X
Safety
Adverse events X X X
Clostridium difficile-associated
diarrhea
X X X
Complications of iv therapy X X X
Laboratory data
The following routine laboratory
results are documented once
from day −3 to 1, if available:
Hemoglobin, red and white
blood cell count, platelet count,
serum sodium, serum potassium,
serum creatinine, liver function
tests, creatine phosphokinase,
C-reactive protein, blood culture
X
Pregnancy test in premenopausal
women
X
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assess the risk-benefit ratio and may lead to (1) stopping
(albeit non-mandatory) due to overwhelming non-
inferiority, (2) stopping for futility/safety, (3) continu-
ation as planned, or (4) recalculation of the sample size
based on conditional power. Any adaptation of the study
design will be based on the observed proportions of
SAB-related late complications applying the inverse nor-
mal method [31].
Trial management
The trial will be managed by the clinical project man-
ager, the team of the CTCC, the principal coordinating
investigator, and the principal investigators at each site.
A Steering Committee was involved in protocol devel-
opment and will oversee study progress. A Scientific
Advisory Committee gives advice on all aspects of the
trial, including trial design. A Clinical Review Committee
will be responsible for evaluating cases regarding protocol
violations, and treatment failures blinded for treatment
arm. A Data Monitoring Committee made up of inde-
pendent experts who are not involved in the conduct of
the trial will oversee the safety of the trial subjects in the
clinical trial by periodically assessing the safety and effi-
cacy of the trial therapy and will monitor the integrity and
validity of the data collected and the conduct of the
clinical trial.
Funding
The clinical trial is funded by the Deutsche Forschungs-
gemeinschaft (DFG; German Research Foundation; grant
number KA 3104/2-1 to A.J.K.). The protocol was en-
dorsed by the European Clinical Research Infrastructure
Network (ECRIN).
Discussion
The SABATO trial will assess whether an early switch to
oral medication is as safe and effective as intravenous
standard therapy. The trial population consists of pa-
tients with a very low risk of SAB-related complications.
Many physicians would feel comfortable with a switch to
oral medication but current guidelines recommend a full
14-day course of intravenous treatment.
The research question will be addressed in a pragmatic
way: patients that have already received 5 to 7 days of
adequate intravenous antimicrobial therapy can be en-
rolled to receive 9 to 7 days of study medication. The
route of administration is determined by randomization,
but the local investigator decides which study drug to
Fig. 2 Analysis sets
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select based on a list of commercially available antimi-
crobials. Patients that receive OST can be discharged
from the hospital.
The primary endpoint-measure - SAB-related complication
- reflects the failure rate of antimicrobial therapy in prevent-
ing late complications. This includes both relapsing SAB
and deep-seated S. aureus infection within 90 days and is
thus the most appropriate clinical outcome measure.
Death unrelated to SAB was not included in the primary
endpoint because this would compromise the power of
the trial by variance inflation. However, all causes of mor-
tality will be carefully assessed and compared.
As an alternative endpoint, we considered “microbio-
logical success,” demonstrated by a negative blood culture
as a test of cure at EOT. Since patients in this trial have
already been treated for 7 days with antimicrobials before
randomization, almost all blood cultures obtained at EOT
are expected to yield a negative result. Therefore, micro-
biological success has not been chosen as an endpoint.
Some researchers feel that the trial is not ambitious
enough by only changing therapy moderately, and be-
lieve that a more aggressive approach, such as testing
7 days of oral medication versus 14 days of intravenous
therapy, should have been undertaken. Although, we
agree that this is an interesting approach, evidence for
its effectiveness is sparse and patient safety is the prime
concern in this trial.
Regarding antimicrobial therapy of SAB, many ques-
tions are unanswered. Although, early oral switch ther-
apy is often applied in other infections, it has never been
assessed in SAB. Therefore, this trial will close gaps in
our understanding and regardless of the result the trial
will influence medical practice.
Trial status
The first patient was recruited on 20 December 2013.
The last patient is expected to be recruited in December
2016. The University of Cologne provides central trial
management and coordination.
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